Predicting osimertinib outcomes in NSCLC using liquid biopsy RWD

ctDNA EGFR status predicts worse survival in NSCLC patients on Osimertinib

INDICATION
Lung
BIOMARKER
EGFR

 

Kaplan-Meier survival curves comparing rwPFS for xF EGFR positive vs negative in pre-treatment xF samples from NSCLC patients anchored on Osimertinib treatment start date. Shaded areas represent the 95% confidence intervals. Median survival times (months) are specified. Log-Rank test P value is indicated.

 

Related cases

Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Grid displaying data points with blue, black, and gray squares on a white background.

RB1 loss-of-function mutations in post-Osimertinib NSCLC and prognostic implications

2026-07-01
Lung
RB1
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Abstract grid of small blue, gray, black, and orange squares on a white background.

Tracking PPM1D post-treatment prevalence to evaluate prognosis in lung adenocarcinoma

2026-07-01
Lung
PPM1D
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Pixelated diagonal gradient with bands of purple, blue, and green dots, resembling data visualization.

PRAME expression and histology impact survival in first-line NSCLC

2026-05-26
Lung
PRAME